U.S. Food and Drug Administration (FDA) · United States
FDA Off-Label Promotion of GLP-1 Weight Loss (Ozempic, Wegovy)
GLP-1 ads must not promote diabetes-only brands for weight loss, imply compounded products are FDA-approved or equivalent to brands, guarantee results, or omit risk information for branded drugs.
What is FDA Off-Label Promotion of GLP-1 Weight Loss (Ozempic, Wegovy)?
GLP-1 ads must not promote diabetes-only brands for weight loss, imply compounded products are FDA-approved or equivalent to brands, guarantee results, or omit risk information for branded drugs. Apply to GLP-1 ads from drug makers, telehealth platforms, med spas, clinics and compounding pharmacies.
GLP-1 ads must not promote diabetes-only brands for weight loss, imply compounded products are FDA-approved or equivalent to brands, guarantee results, or omit risk information for branded drugs.
How can marketing teams comply?
Apply to GLP-1 ads from drug makers, telehealth platforms, med spas, clinics and compounding pharmacies.
What is FDA Off-Label Promotion of GLP-1 Weight Loss (Ozempic, Wegovy)?
GLP-1 ads must not promote diabetes-only brands for weight loss, imply compounded products are FDA-approved or equivalent to brands, guarantee results, or omit risk information for branded drugs.
Supplements, cosmetics, foods and CBD products become unapproved drugs if their marketing claims to diagnose, treat, cure, mitigate or prevent disease, and cosmetics also may not claim to affect body structure or function.
OTC external drug products covered by 21 CFR 358 (warts, corns and calluses, ingrown toenails, lice, dandruff, seborrheic dermatitis, psoriasis) may only claim the uses and actives in their monograph.
Food and supplement labels may link a substance to reduced disease risk only through FDA-authorized or qualified health claims, in the required form, and only on foods meeting nutrient eligibility; disease treatment claims are not allowed.
Infant formula and baby food marketing must not be misleading, including claims of equivalence to breast milk, disease prevention, guaranteed development or absolute contaminant-free status; formulas must meet FDA nutrient and notification requirements.
Firm communications sharing scientific information on unapproved uses with HCPs must follow FDA's January 2025 final SIUU guidance: scientifically sound sources, required disclosures, no persuasive elements, and separation from promotion.
Prescription drug promotion must stay within the approved indication; information on unapproved uses may be shared only separately from promotion under FDA's safe-harbor guidance or in reply to unsolicited requests.
Request a free compliance scan of your homepage and book a time with Warrant.